Inventor · disambiguated record
Mark S. Dennis
Also filed as: DENNIS MARK · DENNIS MARK S
99 granted patents·84 pending applications·1,921 citations·filing 1983–2025
99Inventor score
Top patents by PatentIndex Score
183 records- 0198US7528236B2Humanized anti-beta7 antagonists and uses thereforGENENTECH INC·Filed 2005·Granted May 5, 2009·69 cites·11 claims
- 0297US9708406B2Anti-transferrin receptor antibodies and methods of useGENENTECH INC·Filed 2014·Granted Jul 18, 2017·87 cites·51 claims
- 0397US8545850B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2010·Granted Oct 1, 2013·48 cites·8 claims
- 0496US11912778B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2022·Granted Feb 27, 2024·2 cites·17 claims
- 0596US10143187B2Transferrin receptor transgenic modelsDENALI THERAPEUTICS INC·Filed 2018·Granted Dec 4, 2018·12 cites·34 claims
- 0696US9518118B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2015·Granted Dec 13, 2016·22 cites·29 claims
- 0796US8679490B2Binding polypeptides with diversified and consensus VH/VL hypervariable sequencesDENNIS MARK S·Filed 2006·Granted Mar 25, 2014·77 cites·49 claims
- 0896US8088378B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2008·Granted Jan 3, 2012·48 cites·5 claims
- 0996US7989595B2Compositions and methods for the diagnosis and treatment of tumorGENENTECH INC·Filed 2006·Granted Aug 2, 2011·31 cites·30 claims
- 1096US7476724B2Humanized anti-cmet antibodiesGENENTECH INC·Filed 2005·Granted Jan 13, 2009·103 cites·13 claims
- 1195US11124567B2Anti-TREM2 antibodies and methods of use thereofDENALI THERAPEUTICS INC·Filed 2021·Granted Sep 21, 2021·16 cites·31 claims
- 1295US9896506B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2015·Granted Feb 20, 2018·17 cites·27 claims
- 1395US8771966B2Immuno-PET imaging of antibodies and immunoconjugates and uses thereforGENENTECH INC·Filed 2012·Granted Jul 8, 2014·17 cites·9 claims
- 1495US7892550B2Anti-cmet antibodiesGENENTECH INC·Filed 2006·Granted Feb 22, 2011·79 cites·67 claims
- 1595US5786328AUse of kunitz type plasma kallikrein inhibitorsGENENTECH INC·Filed 1995·Granted Jul 28, 1998·149 cites·4 claims
- 1694US11007267B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2017·Granted May 18, 2021·8 cites·27 claims
- 1794US10865251B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2018·Granted Dec 15, 2020·6 cites·20 claims
- 1894US9611323B2Low affinity blood brain barrier receptor antibodies and uses thereforGENENTECH INC·Filed 2014·Granted Apr 4, 2017·40 cites·17 claims
- 1994US8722857B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2009·Granted May 13, 2014·22 cites·53 claims
- 2094US8691531B2Anti-CD79B antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2011·Granted Apr 8, 2014·20 cites·9 claims
- 2194US8071097B2Apoptotic anti-IgE antibodiesWU LAWREN·Filed 2008·Granted Dec 6, 2011·34 cites·64 claims
- 2293US12162948B2Methods of engineering transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2024·Granted Dec 10, 2024·1 cites·16 claims
- 2393US9975949B2Anti-CD79b antibodies and methods of useGENENTECH INC·Filed 2015·Granted May 22, 2018·13 cites·31 claims
- 2493US8911732B2Anti-mesothelin antibodies and immunoconjugatesDENNIS MARK·Filed 2011·Granted Dec 16, 2014·37 cites·31 claims
- 2593US5780265AKunitz type plasma kallikrein inhibitorsGENENTECH INC·Filed 1995·Granted Jul 14, 1998·125 cites·11 claims
- 2692US10981987B2Humanized anti-CD79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2017·Granted Apr 20, 2021·4 cites·26 claims
- 2792US10808036B2Anti-transferrin receptor antibodies and methods of useGENENTECH INC·Filed 2017·Granted Oct 20, 2020·5 cites·48 claims
- 2892US10752703B2Anti-tryptase antibodies, compositions thereof, and uses thereofGENENTECH INC·Filed 2019·Granted Aug 25, 2020·7 cites·28 claims
- 2992US9845355B2Humanized anti-CD79b antibodies and immunoconjugates and methods of useCHEN YVONNE·Filed 2008·Granted Dec 19, 2017·20 cites·23 claims
- 3092US6113896APharmaceutical compositions containing ecotin and homologs thereofGENENTECH INC·Filed 1994·Granted Sep 5, 2000·80 cites·9 claims
- 3191USRE48558EAnti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2018·Granted May 18, 2021·2 cites·70 claims
- 3291US10174124B2Anti-CD3 antibodies and methods of useGENENTECH INC·Filed 2014·Granted Jan 8, 2019·11 cites·14 claims
- 3391US8449883B2Compositions and methods for the diagnosis and treatment of tumorDENNIS MARK S·Filed 2011·Granted May 28, 2013·12 cites·18 claims
- 3491US8436147B2Antibodies and immunoconjugates and uses thereforDENNIS MARK S·Filed 2007·Granted May 7, 2013·13 cites·44 claims
- 3591US6987088B2Compounds that bind HER2GENENTECH INC·Filed 2002·Granted Jan 17, 2006·42 cites·26 claims
- 3691US5880256AFactor VIIa inhibitors from Kunitz domain proteinsGENENTECH INC·Filed 1995·Granted Mar 9, 1999·75 cites·67 claims
- 3791US5834244AFactor VIIa inhibitors from Kunitz domain proteinsGENENTECH INC·Filed 1995·Granted Nov 10, 1998·82 cites·17 claims
- 3890US10941215B2Low affinity blood brain barrier receptor antibodies and uses thereofGENENTECH INC·Filed 2018·Granted Mar 9, 2021·6 cites·16 claims
- 3990US10179820B2Anti-HER2 antibodies and immunoconjugatesGENENTECH INC·Filed 2016·Granted Jan 15, 2019·6 cites·26 claims
- 4090US7687605B2Humanized anti-beta7 antagonists and uses thereforGENENTECH INC·Filed 2007·Granted Mar 30, 2010·9 cites·9 claims
- 4190US7608681B2Methods and compositions for prolonging elimination half-times of bioactive compoundsGENENTECH INC·Filed 2000·Granted Oct 27, 2009·24 cites·17 claims
- 4290US5843895APharmaceutical administration of ecotin homologsGENENTECH INC·Filed 1995·Granted Dec 1, 1998·64 cites·6 claims
- 4390US5795954AFactor VIIa inhibitors from Kunitz domain proteinsGENENTECH INC·Filed 1994·Granted Aug 18, 1998·81 cites·16 claims
- 4489US11866496B2Humanized anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2021·Granted Jan 9, 2024·1 cites·31 claims
- 4589US8535675B2Compositions and methods for the diagnosis and treatment of tumorDENNIS MARK·Filed 2010·Granted Sep 17, 2013·9 cites·27 claims
- 4689US2024309088A1Anti-cd79b antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2023·Application pending·0 cites
- 4788US11795232B2Engineered transferrin receptor binding polypeptidesDENALI THERAPEUTICS INC·Filed 2019·Granted Oct 24, 2023·2 cites·38 claims
- 4888US10544218B2Anti-CD79B antibodies and immunoconjugates and methods of useGENENTECH INC·Filed 2016·Granted Jan 28, 2020·4 cites·61 claims
- 4988US10508151B2Anti-transferrin receptor antibodies and methods of useGENENTECH INC·Filed 2015·Granted Dec 17, 2019·7 cites·40 claims
- 5088US9266955B2Anti-FGFR4 antibodies and methods of useGENENTECH INC·Filed 2013·Granted Feb 23, 2016·5 cites·8 claims
Showing the top 50 of 183 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Mark S. Dennis files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →